359 related articles for article (PubMed ID: 33901324)
61. IDH2 mutations in patients with normal karyotype AML predict favorable responses to daunorubicin, cytarabine and cladribine regimen.
Libura M; Bialopiotrowicz E; Giebel S; Wierzbowska A; Roboz GJ; Piatkowska-Jakubas B; Pawelczyk M; Gorniak P; Borg K; Wojtas M; Florek I; Matiakowska K; Jazwiec B; Solarska I; Noyszewska-Kania M; Piechna K; Zawada M; Czekalska S; Salamanczuk Z; Karabin K; Wasilewska K; Paluszewska M; Urbanowska E; Gajkowska-Kulik J; Semenczuk G; Rybka J; Wrobel T; Ejduk A; Kata D; Grosicki S; Robak T; Pluta A; Kominek A; Piwocka K; Pyziak K; Sroka-Porada A; Wrobel A; Przybylowicz A; Wojtaszewska M; Lewandowski K; Gil L; Piekarska A; Knopinska W; Bolkun L; Warzocha K; Kuliczkowski K; Sacha T; Basak G; Jedrzejczak WW; Holowiecki J; Juszczynski P; Haus O
Sci Rep; 2021 May; 11(1):10017. PubMed ID: 33976256
[TBL] [Abstract][Full Text] [Related]
62. Standard-Intensity Induction and Intermediate/High-Dose Cytarabine Consolidation Can Improve Survival for Elderly Patients with Newly Diagnosed Acute Myeloid Leukemia: A Retrospective Cohort Study.
Wang L; Zhao N; Zhou L; Tong J; Xue L; Zhang L; Han Y; Wang X; Geng L; Tang B; Liu H; Zhu W; Cai X; Liu X; Zhu X; Sun Z; Zheng C
Clin Interv Aging; 2022; 17():55-64. PubMed ID: 35082491
[TBL] [Abstract][Full Text] [Related]
63. Clinical outcome of treatment with a combined regimen of decitabine and aclacinomycin/cytarabine for patients with refractory acute myeloid leukemia.
Song LX; Xu L; Li X; Chang CK; Zhang Y; Wu LY; He Q; Zhang QX; Li X
Ann Hematol; 2012 Dec; 91(12):1879-86. PubMed ID: 22895556
[TBL] [Abstract][Full Text] [Related]
64. Epigenetic modifier gene mutations-positive AML patients with intermediate-risk karyotypes benefit from decitabine with CAG regimen.
Xu Q; Li Y; Jing Y; Lv N; Wang L; Li Y; Yu L
Int J Cancer; 2020 Mar; 146(5):1457-1467. PubMed ID: 31344264
[TBL] [Abstract][Full Text] [Related]
65. Clofarabine and cytarabine combination as induction therapy for acute myeloid leukemia (AML) in patients 50 years of age or older.
Faderl S; Verstovsek S; Cortes J; Ravandi F; Beran M; Garcia-Manero G; Ferrajoli A; Estrov Z; O'Brien S; Koller C; Giles FJ; Wierda W; Kwari M; Kantarjian HM
Blood; 2006 Jul; 108(1):45-51. PubMed ID: 16403905
[TBL] [Abstract][Full Text] [Related]
66. Delayed-onset effect of clofarabine in the treatment of an adult patient with acute myeloid leukemia.
Walchack R; Cumpston A; Vos J; Kanate AS
Am J Health Syst Pharm; 2019 Feb; 76(6):349-352. PubMed ID: 31361841
[TBL] [Abstract][Full Text] [Related]
67. Efficacy and toxicity of Decitabine in patients with acute myeloid leukemia (AML): A multicenter real-world experience.
Filì C; Candoni A; Zannier ME; Olivieri J; Imbergamo S; Caizzi M; Nadali G; Di Bona E; Ermacora A; Gottardi M; Facchinelli D; Ciancia R; Lazzarotto D; Dubbini MV; Festini G; Gherlinzoni F; Michieli MG; Semenzato G; Fanin R
Leuk Res; 2019 Jan; 76():33-38. PubMed ID: 30529681
[TBL] [Abstract][Full Text] [Related]
68. Decitabine in combination with G-CSF, low-dose cytarabine and aclarubicin is as effective as standard dose chemotherapy in the induction treatment for patients aged from 55 to 69 years old with newly diagnosed acute myeloid leukemia.
Huang J; Hong M; Zhu Y; Zhao H; Zhang X; Wu Y; Lian Y; Zhao X; Li J; Qian S
Leuk Lymphoma; 2018 Nov; 59(11):2570-2579. PubMed ID: 29616840
[TBL] [Abstract][Full Text] [Related]
69. A phase I/II study of oral clofarabine plus low-dose cytarabine in previously treated acute myeloid leukaemia and high-risk myelodysplastic syndrome patients at least 60 years of age.
Buckley SA; Mawad R; Gooley TA; Becker PS; Sandhu V; Hendrie P; Scott BL; Wood BL; Walter RB; Smith K; Dean C; Estey EH; Pagel JM
Br J Haematol; 2015 Aug; 170(3):349-55. PubMed ID: 25854284
[TBL] [Abstract][Full Text] [Related]
70. Hypomethylating agents combined with low-dose chemotherapy for elderly patients with acute myeloid leukaemia unfit for intensive chemotherapy: a real-world clinical experience.
Chen Y; Cao J; Ye Y; Luo L; Zheng X; Yang X; Zheng Z; Zheng J; Yang T; Hu J
J Chemother; 2023 Jul; 35(4):322-329. PubMed ID: 35881409
[TBL] [Abstract][Full Text] [Related]
71. G-CSF priming, clofarabine, and high dose cytarabine (GCLAC) for upfront treatment of acute myeloid leukemia, advanced myelodysplastic syndrome or advanced myeloproliferative neoplasm.
Becker PS; Medeiros BC; Stein AS; Othus M; Appelbaum FR; Forman SJ; Scott BL; Hendrie PC; Gardner KM; Pagel JM; Walter RB; Parks C; Wood BL; Abkowitz JL; Estey EH
Am J Hematol; 2015 Apr; 90(4):295-300. PubMed ID: 25545153
[TBL] [Abstract][Full Text] [Related]
72. [Efficacy, Prognosis and Safety of Decitabine Combined with Low-Dose Cytarabine in the Treatment of Elderly Patients with Relapsed/Refractory Acute Myeloid Leukemia].
Chen D; Lu Y; Yan RZ; Ye PP; Zhang YS; Ma JX
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2019 Apr; 27(2):390-395. PubMed ID: 30998143
[TBL] [Abstract][Full Text] [Related]
73. Survival outcomes and clinical benefit in patients with acute myeloid leukemia treated with glasdegib and low-dose cytarabine according to response to therapy.
Cortes JE; Heidel FH; Fiedler W; Smith BD; Robak T; Montesinos P; Candoni A; Leber B; Sekeres MA; Pollyea DA; Ferdinand R; Ma WW; O'Brien T; O'Connell A; Chan G; Heuser M
J Hematol Oncol; 2020 Jul; 13(1):92. PubMed ID: 32664995
[TBL] [Abstract][Full Text] [Related]
74. Clofarabine doubles the response rate in older patients with acute myeloid leukemia but does not improve survival.
Burnett AK; Russell NH; Hunter AE; Milligan D; Knapper S; Wheatley K; Yin J; McMullin MF; Ali S; Bowen D; Hills RK;
Blood; 2013 Aug; 122(8):1384-94. PubMed ID: 23838349
[TBL] [Abstract][Full Text] [Related]
75. Decitabine combined with medium-dose cytarabine in the treatment of DEK/CAN-positive acute myeloid leukemia: a case report.
Zhang X; Zhang X
Ann Palliat Med; 2021 Apr; 10(4):4955-4958. PubMed ID: 33832283
[TBL] [Abstract][Full Text] [Related]
76. [Comparison of efficacy and prognostic factors in elderly acute myelogenous patients with MA or CAG induction chemotherapy regimen].
Wang J; Jiang B; Jiang Q; Lu J; Zhu HH; Yang SM; Zhao T; Wen L; Bao L; Huang XJ; Jiang H
Zhonghua Xue Ye Xue Za Zhi; 2016 Mar; 37(3):194-200. PubMed ID: 27033755
[TBL] [Abstract][Full Text] [Related]
77. Induction of Acute Myeloid Leukemia with Idarubicin, Cytarabine and Cladribine.
Wiedower E; Jamy O; Martin MG
Anticancer Res; 2015 Nov; 35(11):6287-90. PubMed ID: 26504064
[TBL] [Abstract][Full Text] [Related]
78. Comparison of Reduced-Intensity Idarubicin and Daunorubicin Plus Cytarabine as Induction Chemotherapy for Elderly Patients with Newly Diagnosed Acute Myeloid Leukemia.
Liu H; Fu R; Li L; Wang G; Song J; Ruan E; Wang H; Wu Y; Wang X; Ding K; Shao Z
Clin Drug Investig; 2017 Feb; 37(2):167-174. PubMed ID: 27722823
[TBL] [Abstract][Full Text] [Related]
79. Clinical efficacy of decitabine‑containing induction chemotherapy in de novo non‑elderly acute myeloid leukemia.
Zheng L; Huang L; Hui Y; Huang L; Li Y; Shang Z; Wei J; Wang Z; Mao X; Wang Y; Xiao M; Zhang D
Int J Oncol; 2020 Jun; 56(6):1521-1528. PubMed ID: 32236618
[TBL] [Abstract][Full Text] [Related]
80. A quality-adjusted survival time without symptoms or toxicities analysis of glasdegib plus low-dose cytarabine versus low-dose cytarabine as initial therapy for acute myeloid leukemia in patients who are not considered candidates for intensive chemotherapy.
Solem CT; Bell TJ; Kwon Y; Cappelleri JC; Johnson C; Bhattacharyya H; Hoang CJ; Cortes JE
Cancer; 2020 Oct; 126(19):4315-4321. PubMed ID: 32697335
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
